Celltrion Pharm, Inc.
Clinical trials sponsored by Celltrion Pharm, Inc., explained in plain language.
A pharmaceutical company manufacturing and distributing biosimilars and drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
One pill to tackle two heart risks: new combo therapy tested
Disease control CompletedThis completed Phase 3 trial tested whether a single pill combining ezetimibe, rosuvastatin, and amlodipine can safely lower both cholesterol and blood pressure in 163 Korean adults with hypertension and high cholesterol. Participants took the combination pill or a control for 8 …
Phase 3 • Sponsor: Celltrion Pharm, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Diabetes drug showdown: which Add-On works best?
Disease control CompletedThis study tested whether adding pioglitazone or dapagliflozin to standard diabetes pills (alogliptin and metformin) helps control blood sugar better in adults with type 2 diabetes. A total of 133 participants took one of the two extra drugs for 26 weeks. The main goal was to see…
Phase 4 • Sponsor: Celltrion Pharm, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC